Medication-assisted treatment is widely accepted treatment for patients with opioid use disorders. Still, patients have many reasons, spoken and unspoken, to be reluctant to start this potentially life-saving treatment. On this episode, Ashley Braun-Gabelman, PhD, discusses the importance of addressing this resistance and why it's important to explore this barrier to treatment head on. Dr. Braun Gabelman is a clinical psychologist in Addiction Recovery Services at University Hospitals Cleveland Medical Center and an Assistant Professor in the Department of Psychiatry at Case Western Reserve University School of Medicine. She specializes in the treatment of substance use and co-occurring disorders including major depression, anxiety disorders, and PTSD.
Today we discuss non-opioid pharmacological management of chronic pain with Dr. Kevin Sevarino. Dr. Sevarino received his Doctorate of Medicine in 1982 from McGill University and his Ph.D. in Molecular Biology in 1983 from the University of Connecticut. He is an Assistant Clinical Professor of Psychiatry at Yale University and the University of Connecticut Schools of Medicine. Dr. Sevarino is an active clinician, serving as Medical Director attending for the VA Connecticut Healthcare System Newington Mental Health Firm. He is director of the Addictions and He is Medical Director of SAMHSA’s Providers’ Their Treatment Course for the American Academy of Addiction Psychiatry for eight years, and is Vice President for that organization. He is Medical Director of SAMHSA’s Providers' Clinical Support System for Opioid Therapies. His main interests are in treating those with chronic pain and opioid use disorders and in developing new ways to educate primary care providers in safe and responsible opioid prescribing.
Today we will be talking about the use of naltrexone for the treatment of opioid use disorder therapy. Naltrexone is an opioid blocker, or antagonist, that has limited prevalence of use compared with buprenorphine, a partial agonist, and methadone, a long-acting agonist. Joining us for this conversation is Dr. Adam Bisaga, an academic psychiatrist, educator and clinician. He is a Professor of Psychiatry at the Columbia University Medical Center, and a Research Scientist at the New York State Psychiatric Institute. He was a recipient of a Career Development Award and a Principal Investigator on grants funded by the National Institute of Drug Abuse. His research interests include development of human laboratory and clinical trial models for testing medications to treat substance use disorders, including trials to improve effectiveness of antagonist-based treatment of opioid use disorder. Dr. Bisaga publishes and lectures in the area of addiction research and he is a member of the editorial board of the journal Addiction.